Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in immunoconjugate cancer therapeutics.

Gillian Payne1

  • 1ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139, USA. gillian.payne@immunogen.com

Cancer Cell
|April 5, 2003
PubMed
Summary

Immunoconjugate technology advances offer new cancer "magic bullet" immunotherapeutics. Enhanced antibody production and potent effector molecules improve targeted cancer treatment potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4).

Heart (British Cardiac Society)·2024
Same author

An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities.

Molecular cancer therapeutics·2020
Same author

Identification and characterization of co-purifying CHO host cell proteins in monoclonal antibody purification process.

Journal of pharmaceutical and biomedical analysis·2019
Same author

Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples.

The AAPS journal·2017
Same author

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Molecular cancer therapeutics·2015
Same author

Assessment of an incidental finding of left bundle-branch block.

British journal of hospital medicine (London, England : 2005)·2015

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Immunoconjugate technology revives the
  • magic bullet
  • concept for cancer immunotherapy.
  • Genomics and proteomics have expanded the repertoire of tumor-specific antibodies.
  • Advances in medicinal and radionuclide chemistry are crucial for developing potent effector molecules.

Purpose of the Study:

  • To highlight the advancements in immunoconjugate technology for cancer treatment.
  • To discuss the role of antibody engineering and effector molecule development.
  • To underscore the potential of novel immunotherapeutics in oncology.

Main Methods:

  • Review of recent developments in antibody production and characterization.
  • Analysis of strategies for identifying and producing tumor-specific antibodies.
  • Exploration of medicinal and radionuclide chemistry for effector molecule design.

Main Results:

  • Significant progress in developing human antibodies and expanding epitope targets.
  • Increased potential for targeted cancer therapies through improved antibody identification and production.
  • Development of highly potent effector molecules suitable for antibody delivery.

Conclusions:

  • Immunoconjugate technology represents a promising frontier in cancer immunotherapy.
  • The synergy between antibody engineering and effector molecule development is key to therapeutic success.
  • Further research in these areas holds significant potential for novel cancer treatments.

Related Experiment Videos